Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25406359
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Indications for IVIG in rheumatic diseases
#MMPMID25406359
Mulhearn B
; Bruce IN
Rheumatology (Oxford)
2015[Mar]; 54
(3
): 383-91
PMID25406359
show ga
The use of IVIG to treat a wide variety of immune-driven diseases has grown
rapidly, although the mechanism of action is not completely understood.
Increasing demand for IVIG coupled with concerns regarding potential
transmissible agents has led to worldwide supply shortages. National agencies
have therefore produced guidelines for its use, with the latest England and Wales
guideline being published in 2011. Due to the rarity of the rheumatic diseases,
the evidence for IVIG use has been shown to be lacking in some areas and
promising in others. Conditions in which IVIG has been shown to have benefit
include ITP, Guillain-Barré syndrome and chronic inflammatory demyelinating
polyneuropathy occurring in the context of rheumatic disease, as well as in SLE,
idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review
looks at current IVIG use and is designed to be an aid for rheumatologists when
considering the use of IVIG in clinical practice.
|Humans
[MESH]
|Immunoglobulins, Intravenous/adverse effects/*therapeutic use
[MESH]
free
free
free
